Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: carbon monoxide measurement via smokerlyzer for Liver Cancer Adult

The investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection or ablation(2) to assess the production of CO in patients following liver resection or ablation and correlate these findings to the rate of liver regeneration and liver function.

Official registry: https://clinicaltrials.gov/study/NCT06681818 · Englewood Hospital and Medical Center · enrollment listed as 125

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are carbon monoxide measurement via smokerlyzer. The registry lists allocation as na. The investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection or ablation(2) to assess the production of CO in patients following liver resection or ablation and correlate these findings to the rate of liver regeneration and liver function.

They plan to enroll about 125 people at Englewood. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

Interventions: carbon monoxide measurement via smokerlyzer

Primary outcome (registry wording): correlation of carbon monoxide levels in exhaled breath with quantity and quality of liver regeneration

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Patient plans to have an ablation or partial liver resection for primary liver pathology or metastatic disease
  • Patient is able to comprehend and willing to sign the written consent form

Public study contact (from the registry)

Jamie Ketas

2018943418

jamie.ketas@ehmchealth.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT06681818 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06681818?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06681818?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary